Displayed reflectivity of choroidal neovascular membranes by optical coherence tomography correlates with presence of leakage by fluorescein angiography

Retina

Volumn 31, Issue 5, 2011, Pages 942-948

  Giani, Andrea ^a,b   Esmaili, Daniel D ^a   Luiselli, Cristiano ^b   Cigada, Mario ^b   Salvetti, Paola ^b   Miller, Joan W ^a   Staurenghi, Giovanni ^b  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Age related macular degeneration; choroidal neovascularization; fluorescein angiography; optical coherence tomography; optical reflectivity

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIUM; RATING SCALE; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; CAPILLARY PERMEABILITY; CHOROID; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; MALE; MEMBRANES; PILOT PROJECTS; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 79955557262     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31820a68cc     Document Type: Article

References (23)

1. Klaver CC, Wolfs RC, Assink JJ, van Dujin CM, Hofman A, de Jong PT. Genetic risk of age-related maculopathy. Population-based familial aggregation study. Arch Ophthalmol 1998;116:1646-1651. (Pubitemid 29001964)
2. Klein R, Klein BE, Jensen SC. The relation of cardiovascular disease and its risk factors to the 5-year incidence of agerelated maculopathy: the Beaver Dam Eye Study. Ophthalmology 1997;104:1804-1812. (Pubitemid 28100335)
3. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1232-1241.
4. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 1999;117:1161-1173. (Pubitemid 29428825)
5. Blinder KJ, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003;136: 407-418. (Pubitemid 37101236)
6. Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment-TAP and VIP report no. 2. Arch Ophthalmol 2003;121:1253-1268.
7. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinson M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816. (Pubitemid 40051904)
8. Hee MR, Baumal CR, Puliafito CA, et al. Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. Ophthalmology 1996;103:1260-1270. (Pubitemid 26282510)
9. Wojtkowski M, Leitgeb R, Kowalczyk A, Bajraszewski T, Fercher AF. In vivo human retinal imaging by Fourier domain optical coherence tomography. J Biomed Opt 2002;7:457-463.
10. Sayanagi K, Sharma S, Yamamoto T, Kaiser PK. Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab. Ophthalmology 2009;116:947-955.
11. Menke MN, Dabov S, Sturm V. Features of age-related macular degeneration assessed with three-dimensional Fourierdomain optical coherence tomography. Br J Ophthalmol 2008; 92:1492-1497.
12. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2005. ISBN 3-900051-07-0. Available at: http://www.R-project.org. Accessed November 16, 2010.
13. Holz FG, Jorzik J, Schutt F, Flach U, Unnebrink K. Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study). Ophthalmology 2003;110:400-405. (Pubitemid 36184347)
14. Kwan AS, Barry C, McAllister IL, Constable I. Fluorescein angiography and adverse drug reactions revisited: the Lions Eye experience. Clin Experiment Ophthalmol 2006;34:33-38. (Pubitemid 43379368)
15. Ozdemir H, Karacorlu SA, Karacorlu M. Early optical coherence tomography changes after photodynamic therapy in patients with age-related macular degeneration. Am J Ophthalmol 2006;141:574-576. (Pubitemid 43265973)
16. Eter N, Spaide RF. Comparison of fluorescein angiography and optical coherence tomography for patients with choroidal neovascularization after photodynamic therapy. Retina 2005; 25:691-696. (Pubitemid 41254537)
17. Drexler W, Fujimoto JG. State-of-the-art retinal optical coherence tomography. Prog Retin Eye Res 2008;27:45-88. (Pubitemid 351165776)
18. Liakopoulos S, Ongchin S, Bansal A, et al. Quantitative optical coherence tomography findings in various subtypes of neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2008;49:5048-5054.
19. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and agerelated macular degeneration. Prog Retin Eye Res 2001;20: 705-732. (Pubitemid 32918285)
20. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-389. (Pubitemid 40530070)
21. Kamei M, Hollyfield JG. TIMP-3 in Bruch's membrane: changes during aging and in age-related macular degeneration. Invest Ophthalmol Vis Sci 1999;40:2367-2375. (Pubitemid 29418393)
22. Penfold PL, Madigan MC, Gillies MC, Provis JM. Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res 2001;20:385-414. (Pubitemid 32245687)
23. Izumi-Nagai K, Nagai N, Ohgami K, et al. Inhibition of choroidal neovascularization with an anti-inflammatory carotenoid astaxanthin. Invest Ophthalmol Vis Sci 2008;49: 1679-1685.